Gut microbiome to predict efficacy and immune-related toxicities in patients with advanced non-small cell lung cancer treated with anti-PD-1/PD-L1 antibody-based immunotherapy.
Gut microbiome to predict efficacy and immune-related toxicities in patients with advanced non-small cell lung cancer treated with anti-PD-1/PD-L1 antibody-based immunotherapy.
复制标题
DOI：
10.1200/jco.2020.38.15_suppl.3095
复制
发表时间：
2020-05
影响因子：
45.3
通讯作者：
T. Hakozaki;C. Richard;Y. Okuma;L. Derosa;A. Elkrief;L. Zitvogel;B. Routy;Y. Hosomi
中科院分区：
文献类型：
--
作者：
T. Hakozaki;C. Richard;Y. Okuma;L. Derosa;A. Elkrief;L. Zitvogel;B. Routy;Y. Hosomi
3095背景：肠道微生物组（GM）在形成全身免疫应答中起重要作用。临床前和临床数据表明，GM影响抗PD-1/PD-L1或CTLA-4抗体（A...
3095Background: The gut microbiome (GM) plays an important role in shaping systemic immune responses. Preclinical and clinical data suggest that GM influences anti-PD-1/PD-L1 or -CTLA-4 Antibody (A...